We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

49 hedge funds and large institutions have $250M invested in Adaptimmune Therapeutics in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 2 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

850% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 2

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

38% more capital invested

Capital invested by funds: $181M → $250M (+$68.6M)

20% more funds holding

Funds holding: 41 → 49 (+8)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
49
Holders Change
+8
Holders Change %
+19.51%
% of All Funds
1.29%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
21
Increased
19
Reduced
2
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$28.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.4M
3
Fidelity International
Fidelity International
Bermuda
+$6.53M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$5.68M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.9M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$16.9M
2
PHS
PFM Health Sciences
California
-$12M
3
Citadel Advisors
Citadel Advisors
Florida
-$7.84M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.42M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$1.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$79.5M +$17.4M +1,772,294 +37%
Capital World Investors
2
Capital World Investors
California
$55.5M +$28.3M +2,887,082 +168%
FCMI
3
Foresite Capital Management II
California
$21.2M +$42.1K +4,299 +0.2%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$10.3M +$4.9M +500,000 +143%
RSCM
5
Rock Springs Capital Management
Maryland
$9.23M +$87.2K +8,901 +1%
Fidelity International
6
Fidelity International
Bermuda
$9.09M +$6.53M +666,891 +768%
QF
7
QVT Financial
New York
$8.03M +$3.09M +315,566 +90%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$7M +$5.68M +580,173 New
Jennison Associates
9
Jennison Associates
New York
$5.87M +$15.2K +1,547 +0.3%
O
10
OrbiMed
New York
$5.29M +$2.57M +262,314 +149%
IHM
11
Iguana Healthcare Management
New York
$4.26M +$2.72M +278,161 +371%
Millennium Management
12
Millennium Management
New York
$4.16M +$1.53M +156,724 +83%
EAM
13
EverPoint Asset Management
Connecticut
$3.92M +$3.18M +325,000 New
TCM
14
Tekla Capital Management
Massachusetts
$3.58M +$147K +15,000 +5%
A
15
Abingworth
United Kingdom
$3.01M +$2.45M +250,000 New
UBS AM
16
UBS AM
Illinois
$2.55M -$163K -16,645 -7%
GTC
17
Ghost Tree Capital
New York
$2.53M +$2.06M +210,000 New
Marshall Wace
18
Marshall Wace
United Kingdom
$1.7M +$1.38M +140,983 New
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$1.57M +$1.28M +130,200 New
RG
20
Rathbones Group
United Kingdom
$1.51M +$1.96M +200,525 New
WMSA
21
Weiss Multi-Strategy Advisers
New York
$1.24M -$137K -14,000 -12%
BBA
22
Baker Bros. Advisors
New York
$1.21M – – –
VIA
23
Vident Investment Advisory
Georgia
$911K +$740K +75,540 New
State Street
24
State Street
Massachusetts
$794K +$644K +65,800 New
RIM
25
RS Investment Management
California
$760K +$617K +62,980 New
1
2 3

ADAP Hedge Fund Activity: Q4 2015 in Review

49 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2015, worth a combined $250M — up 38% from $181M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ADAP positions and 13 closed out — a net gain of 8 holders — while 19 added to existing stakes and 2 trimmed.

The largest buyer was Capital World Investors, adding an estimated $28.3M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $16.9M sold.

  • 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2015, up from 41 in Q3 2015.
  • Funds reported $250M of Adaptimmune Therapeutics stock for Q4 2015, up 38% quarter-over-quarter.
  • 21 funds opened new Adaptimmune Therapeutics positions in Q4 2015 and 13 closed out, a net change of +8 holders.
  • The largest Adaptimmune Therapeutics buyer in Q4 2015 was Capital World Investors, an estimated $28.3M added.
  • The largest Adaptimmune Therapeutics seller in Q4 2015 was Novo Holdings A/S, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2015.